SUPERCHARGED PROTEINS FOR CELL PENETRATION
6 Assignments
0 Petitions
Accused Products
Abstract
Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. The systems and methods may involve altering the primary sequence of a protein in order to “supercharge” the protein (e g, to generate a superpositively-charged protein). The compositions may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc.
-
Citations
80 Claims
-
1. (canceled)
-
2. (canceled)
-
3. A method of introducing a supercharged protein, or an agent associated with a supercharged protein, or both, into a cell, comprising:
contacting said supercharged protein, or a supercharged protein and an agent associated with the supercharged protein with said cell under conditions sufficient to allow penetration of said supercharged protein, or said agent associated with a supercharged protein, into the cell, thereby introducing a supercharged protein, or an agent associated with a supercharged protein, or both, into a cell. - View Dependent Claims (4)
-
5. A complex comprising:
-
a supercharged protein, wherein the supercharged protein has an overall net charge greater than its corresponding unmodified protein; and one or more nucleic agents. - View Dependent Claims (6, 7, 15, 16, 21, 23, 28, 34, 37, 38, 39, 41, 48, 51, 78, 79)
-
-
8-15. -15. (canceled)
-
17-20. -20. (canceled)
-
22. (canceled)
-
24-27. -27. (canceled)
-
29-33. -33. (canceled)
-
35-36. -36. (canceled)
-
40. (canceled)
-
42-47. -47. (canceled)
-
49-50. -50. (canceled)
-
52-57. -57. (canceled)
-
58. A complex comprising:
-
a protein selected from the group consisting of cyclon (ID No.;
Q9H6F5), PNRC1 (ID No.;
Q12796), RNPS1 (ID No.;
Q15287), SURF6 (ID No.;
O75683), AR6P (ID No.;
Q66PJ3), NKAP (ID No.;
Q8N5F7), EBP2 (ID No.;
Q99848), LSM11 (ID No.;
P83369), RL4 (ID No.;
P36578), KRR1 (ID No.;
Q13601), RY-1 (ID No.;
Q8WVK2), BriX (ID No.;
Q8TDN6), MNDA (ID No.;
P41218), H1b (ID No.;
P16401), cyclin (ID No.;
Q9UK58), MDK (ID No.;
P21741), PROK (ID No.;
Q9HC23), FGF5 (ID No.;
P12034), SFRS (ID No.;
Q8N9Q2), AKIP (ID No.;
Q9NWT8), CDK (ID No.;
Q8N726), beta-defensin (ID No.;
P81534), PAVAC (ID No.;
P18509), eotaxin-3 (ID No.;
Q9Y258), histone H2A (ID No.;
Q7L7L0), and HMGB1 (ID No.;
P09429); andone or more polynucleotides, peptides, proteins, or small molecules.
-
-
59-77. -77. (canceled)
-
80-93. -93. (canceled)
Specification